GlaxoSmithKline Stock News

Investment bank Jefferies has kept its ‘buy' rating and 2,500p target on GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 drugmaker, after a fireside chat with its chief scientific officer reinforced its view that B7H3 is one of GSK's most underappreciated opportunities. The target implies 35% upside from the prior close of 1,851p, while GSK had a market capitalisation of £74.9 billion.

European drugmakers called for ​beefed-up government spending on medicines, faster trials and IP protections as ‌they sounded warnings on Tuesday that the continent's pharmaceutical industry risks losing out to the United States and China.

GSK said on Tuesday it had agreed a deal worth up to $750 million ​to buy a trispecific T cell-engager (TCE), a drug ‌designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences.

GSK said on Friday it will be shutting down ​a vaccine factory in Dresden, Germany, which ‌its website showed produces flu and hepatitis shots, in the summer of 2027.

GSK PLC's (LSE:GSK, NYSE:GSK)  experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.

Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market co...

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau an...